1. Dubertret L et al. European patient perspectives on the impact of psoriasis:
the EUROPSO patient membership survey. Brit J Dermatol 2006; 155: 729–36.
2. Horn E, NPF USA, Homepage at http://www.psoriasis.org/home/. 2007.
3. Winterfield LS et al. Ann Reum Dis 2005; 64 (Suppl. II): 87–90.
4. Morimoto S et al. An open study of vitamin D3 treatment in psoriasis vulgaris.
Brit J Dermatol 1986; 115: 421.
5. Kragballe K et al. Long-term efficacy and tolerability of topical calcipotriol
in psoriasis. Acta Derm Venerol (Stockh) 1991; 71: 475.
6. Yu X-P et al. Down-regulation of NF-kappa B protein levels in activated
human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA
1995; 92.
7. Bagot M et al. Immunosuppressive effects of 1,25-dihydroxyvitamin D3 and
its analogues calcipotriol on epidermal cells. Brit J Dermatol 1994; 130: 1994.
8. Menter A, Smith C, Barker J. Psoriasis. Oxford, Health Press, 2004.
Авторы
Л.М.Смирнова, Н.Г.Кочергин, У.Г.Билалова
Первый МГМУ им. И.М.Сеченова